The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 4 of the 27 sources its claims cite were checked for support.
Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation
Open accessAbstract
Apolipoprotein (apo) E mutants are associated with type III hyperlipoproteinemia characterized by high cholesterol and triglycerides levels. Autosomal dominant hypercholesterolemia (ADH), due to the mutations in the LDLR, APOB, or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to the high levels of low-density lipoproteins (LDLs). We now report an exceptionally large family including 14 members with ADH. Through genome-wide mapping, analysis of regional/functional candidate genes, and whole exome sequencing, we identified a mutation in the APOE gene, c.500_502delTCC/p.Leu167del, previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia. We confirmed the involvement of the APOE p.Leu167del in ADH, with (1) a predicted destabilization of an alpha-helix in the binding domain, (2) a decreased apo E level in LDLs, and (3) a decreased catabolism of LDLs. Our results show that mutations in the APOE gene can be associated with bona fide ADH.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This paper reports an exceptionally large French family with autosomal dominant hypercholesterolemia (ADH) in which linkage mapping and exome sequencing identified the APOE p.Leu167del mutation as the likely cause. The authors conclude that APOE mutations can be associated with bona fide ADH and that APOE screening is warranted alongside LDLR, APOB, and PCSK9 in ADH molecular diagnosis.
Key findings
- In the HC126 family, genome-wide linkage gave a maximum LOD score of 2.55 (θ=0) at rs718087 on chromosome 19; multipoint analysis at 19q13.31–13.32 gave a maximum LOD score of 3.15 between rs1988065 and rs3513657 (19:43,374,601–45,439,163).
- The APOE c.500_502delTCC (p.Leu167del) mutation was identified and was not detected in over 220 controls. Additional APOE variants p.Arg269Gly and p.Arg235Trp were found in non-LDLR/APOB/PCSK9 probands and were absent in over 500 French controls.
- Two p.Leu167del carriers had total apo E levels of 4.09 mg/dL and 4.03 mg/dL, both within the normal range (2.30–6.30 mg/dL); apo E distribution showed a higher proportion in HDL (77% vs 63–69%) and a lower proportion in LDL (12% vs 18–25%).
- In one carrier after a 2-month washout, lipid values were triglycerides 3.7, total cholesterol 10.5, LDL-cholesterol 8.1, and HDL-cholesterol 0.7 mmol/L; LDL kinetics resembled those of familial hypercholesterolemia patients, with an increased LDL pool due to increased LDL production and decreased LDL catabolism. No splenomegaly or thrombocytopenia was present in the 12 APOE p.Leu167del carriers of HC126 nor in the proband of HC512.
Methods
- ADH families were recruited by the French National Research Network on Hypercholesterolemia; the HC126 family was initiated through proband II-2 and expanded to 27 individuals over 3 generations, exploring 23 meioses. Inclusion criteria included total and LDL-cholesterol above the 95th percentile, triglycerides below 1.5 mmol/L, and personal and/or documented familial xanthomas and/or early coronary artery disease.
- The study combined genome-wide linkage mapping (with 100,000 simulations; av.ELOD 2.1, max.ELOD 4.8), regional microsatellite/multipoint analysis, candidate gene sequencing, and whole exome sequencing in three affected members (III-2, III-7, III-8).
- APOE p.Leu167del was screened by direct fluorescent PCR in controls, and the APOE gene was sequenced in 153 non-LDLR/APOB/PCSK9 probands (55 French ADH and 98 Norwegian hyperlipidemics). The authors also performed homology modeling, measured apo E levels and lipoprotein distribution, and conducted in vivo apo B-100 kinetic studies in one patient after washout.
Limitations
- Stated: the apo E distribution data need confirmation because they are based on only two patients, including one under lipid-lowering therapy; the kinetic data need confirmation because they are based on only one patient.
- Stated: a LDL receptor-binding defect could not be directly excluded, and a prior in vitro competitive binding test with apo E from a heterozygous p.Leu167del carrier showed no significant binding defect, so the effect of the deleted mutant alone could not be observed.
- Evident: the small number of mutation carriers limits biochemical and kinetic conclusions; the family also includes possible phenocopies (I-3 and II-14) and an unclassified patient (II-5), suggesting another lipid abnormality in the family remains unidentified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 27 cited sources checked · 1 supported · 1 flagged · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Among 9 non-LDLR/-APOB/-PCSK9/-HCHOLA4 families we have identified, one was large enough to enable genome wide mapping of a new ADH gene (Marques-Pinheiro A et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Disputedcites Marques-Pinheiro A et al. 2010 sourceExperimental — accuracy not yet measured
The Abstract and Linkage analysis section distinguish the large family used to map HCHOLA4 from the nine families that excluded linkage to that locus. The paper therefore does not place the genome-mapped family among those nine; it says the opposite. Our copy provides no page numbers for these passages. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“at least 19% of ADH families in which the disease is not associated with a mutation within one of these three genes (Marduel M et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Partly supportedcites Marduel M et al. 2010 sourceExperimental — accuracy not yet measured
The Results and Discussion report that no mutation in LDLR, APOB or PCSK9 was identified in 258 of 1,358 French ADH probands (19.0%). This supports the percentage for that cohort, but the claim extends it to ADH families generally and treats an unidentified mutation as evidence that no mutation in those genes is associated with their disease. (LLM, conf=0.85)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Regional haplotype construction allowed the identification of a common region for affected members from D19S417 to D19S908 (Figure 1A).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Phenotypically unclassified patient II-5 did not carry the familial-disease haplotype”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Through genome wide mapping, analysis of regional/functional candidate genes and whole exome sequencing, we identified a mutation in the APOE gene, p.Leu167del”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a decreased catabolism of LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The p.Leu167del variation interrupts one α helix in a group of four helices stabilized by a leucine zipper.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the c.500_502delTCC (p.Leu167del, formerly called Δ149Leu) variation in the APOE gene (RefSeq NM_000041.2) was found”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a decreased apo E level in LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After this period, the lipid values for this patient were: 3.7, 10.5, 8.1 and 0.7 mmol/L for triglycerids, total-, LDL- and HDL-cholesterol respectively.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 16
- It may state two separate claims as one. 24
- The quote only partly states this claim. 1
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“new ADH loci were recently mapped at 16q22.1, HCHOLA4 (Marques-Pinheiro A et al. 2010), and 8q24.22 (Cenarro A et al. 2011).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Supportedcites Marques-Pinheiro A et al. 2010 source
The Discussion states that a genome-wide scan in a large French family mapped a fourth ADH locus at 16q22.1. The Introduction names that locus HCHOLA4. The 8q24.22 locus is attributed to a different citation in the citing sentence, so it is not part of this verdict. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Cenarro A et al. 2011 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“VLDL and IDL kinetic parameters were in accordance with the high triglyceride level only observed for this measurement, and never before in this patient, showing similarities with a type III hyperlipoproteinemia (E2E2 genotype) such as the dramatically increased VLDL and IDL pool due to a decreased conversion rate (Ooi EM et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Partly supportedcites Ooi EM et al. 2010 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Leu167 of apoE is not a conserved amino acid, but is the fourth residue in a 6 amino acid motif of which positions 1, 2, 3 and 6 are very well conserved from Xenopus tropicalis to Homo sapiens (Supp. Figure S3).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No splenomegaly or thrombocytopenia were present in the 12 APOE p.Leu167del carriers of the HC126 family nor in the proband of HC512 indicating that these subjects did not present the sea-blue histiocytosis disease.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The APOE p.Leu167del was not detected in over 220 controls, in agreement with Faivre et al. who had investigated 50 French controls, and indicating that this apo E variation is not a frequent polymorphism.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Faivre L et al. 2005 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The two first variants were shown to be frequent genomic variants (//snp.gs.washington.edu/EVS/, //www.1000genomes.org), excluding them from being a possible disease-causing mutation.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The recruitment of the HC126 family was initiated through the female proband II-2, and expanded to 27 individuals over 3 generations, thus exploring 23 meioses (Figure 1A).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, the increased VLDL and IDL pool for the HC126 patient was also due to an increased production rate, that was not observed for E2E2 patients, but already reported for patients carrying a PCSK9 gene mutation (Ouguerram K et al. 2003).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Ouguerram K et al. 2003 source
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apo E distribution in each lipoprotein fraction showed a higher proportion in HDL (77% vs 63–69%), and a lower proportion in LDL (12% vs 18–25%) (Supp. Table S3).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDL kinetic parameters were similar to those from FH patients (mutation in the LDLR gene) with an increased LDL pool, which was the consequence of both an increase in LDL production rate and a decrease in LDL catabolism (Table 1).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CEACAM8 variant is rare, 3/10755 in the Exome Variant Server and not reported by the “1000 genome” project.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“rare apo E mutants have been described associated with type III hyperlipoproteinemia or lipoprotein glomerulopathy (OMIM +611771).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM +611771
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Apo E2 isoform is associated with lower LDL cholesterol, except for 5% of E2/E2 carriers who develop type III hyperlipoproteinemia (OMIM +107741)”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM +107741
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
In the paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Abifadel M et al. 2003 source
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, IDL production is increased and, combined to the low IDL catabolism, leads to an increased LDL production.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The APOE p.Leu167del mutation was reported in subjects with familial combined hyperlipidemia (FCHL, type III dyslipoproteinemia) (Solanas-Barca M et al. 2012) and in the HC126 family reported here with a bona fide ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Solanas-Barca M et al. 2012 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Apo E4 isoform is associated with elevated total and LDL-cholesterol levels, due to the higher affinity of apo E4 for VLDL and LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Hatters DM et al. 2006 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“a few rare apo E variants (p.Glu21Lys, p.Pro102Arg and, p.Leu270Glu) have been observed in probands with hyperLDLemia (type IIa hyperlipoproteinemia), but none co-segregated with hyperLDLemia in the families (Wardell MR et al. 1991, van den Maagdenberg AM et al. 1993).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Wardell MR et al. 1991 source
- Not checked — no full text of the sourcecites van den Maagdenberg AM et al. 1993
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, these data need to be confirmed because they are based on the study of only two patients, including one under a lipid lowering therapy.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The other mutations, p.Arg235Trp and p.Arg269Gly, are at the origin of a loss of charge in the first and second α helices of the C-terminal domain that very probably change each helix’s properties, interaction with lipoproteins, and receptor binding.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, these data need to be confirmed because they are based on the study of only one patient.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“The p.Arg269Gly apo E mutant has been previously reported in a proband with type IIb hyperlipoproteinemia, differing from ADH by elevated plasma triglyceride levels (Wardell MR et al. 1991).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Wardell MR et al. 1991 source
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Whereas apo E3 and apo E4 bind with similarly high affinity to the LDL receptor, the binding of apo E2 is 50- to 100- times weaker (Weisgraber KH et al. 1982).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Weisgraber KH et al. 1982 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“as well as the two affected members I-3 and II-14 who highly probably display a phenocopy form of ADH”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
In the paper
“The APOE gene accounts for a significant fraction of the variation in plasma cholesterol levels (Eichner JE et al. 2002).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Eichner JE et al. 2002 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, both hypotheses are in agreement with a decreased catabolism of LDL bearing apo E p.Leu167del and thus explaining the hyperLDLemia observed in the family.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mutations in the LDLR or APOE gene may amplify the effect of these factors, and thus, according to the number or the nature of these factors, could be associated with an overlapping phenotype between FCHL and ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDL kinetic parameters of apo E mutant carrier were similar to those from FH patients strengthening the very probable effect of LDL bearing an apo E mutant on their catabolism.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Abifadel M et al. 2003 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The APOE p.Leu167del mutation was reported to be associated with sea-blue histiocytosis (OMIM #26960)”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM #26960
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The electrostatic surface charges are altered in apo E p.Leu167del, that also likely influences interaction with lipids and affinity of apo E to its receptors.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The APOE p.Leu167del mutation was also reported in subjects with familial combined hyperlipidemia (FCHL, type III dyslipoproteinemia) (Solanas-Barca M et al. 2012).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Solanas-Barca M et al. 2012 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
A compensatory increased activity of the normal apoE in the presence of the deleted mutant could mask a LDL receptor-binding defect.
“under the hypothesis of a compensatory increased activity of the normal apoE in the presence of the deleted mutant”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“FH due to APOE deficiency is recessively inherited, as in APOE-deficient homozygotes, but APOE variants diagnosed as ADH have also been reported29).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequently, whole-exome sequencing and functional analysis of large French and Italian families containing many FH patients revealed that APOE p.Leu167del (Leu149del) is involved in ADH29, 57, 118).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Within a Norwegian hyperlipidemic cohort, APOE p.Arg235Trp (Arg217Trp) was found in a 56-year-old man with total cholesterol, triglyceride, LDL, and HDL levels of 363, 239, 247, and 69.6 mg/dL, respectively, along with the apoE3/E4 isoforms29).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Of the 11 cases of APOE deficiency with reported mutation sites, four were homozygotes and seven were compound heterozygotes or heterozygotes27, 29-40).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cenarro study is cited with two different years
MinorThe text cites the 8q24.22 locus study as published in 2011, but the matching reference lists its publication year as 2010.
“8q24.22 (Cenarro A et al. 2011)”
“4. Cenarro A Garcia-Otin AL Tejedor MT Solanas M Jarauta E Junquera C Ros E Mozas P Puzo J Pocovi M Civeira F 2010 A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22 Clin Genet 20629670”
Citations
Cites
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationThe Metabolic Basis of Inherited Diseases
WINKELMANN, R. K. (1972) · Archives of Dermatology · doi:10.1001/archderm.1972.01620110090032 · Cited by 1,766
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 3×
“Apo E distribution in each lipoprotein fraction showed a higher proportion in HDLs (77% vs. 63%– 69”
BackgroundInfluentialMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Siest, G., Visvikis‐Siest, S., Herbeth, B., Gueguen, R., Vincent‐Viry, M., Sass, C., Beaud, B., Lecomte, E., Steinmetz, J., Locuty, J., et al. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.007 · Cited by 140
Molecular spectrum of autosomal dominant hypercholesterolemia in France
Marduel, M., Carrié, A., Sassolas, A., Devillers, M., Carreau, V., Di Filippo, M., Erlich, D., Abifadel, M., Marques-Pinheiro, A., Munnich, A., et al. (2010) · Human Mutation · doi:10.1002/humu.21348 · Cited by 115
Self-citationCiveira, F., Jarauta, E., Cenarro, A., García-Otín, A. L., Tejedor, D., Zambón, D., Mallén, M., Ros, E., & Pocovı́, M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.050 · Cited by 84
Solanas-Barca, M., de Castro-Orós, I., Mateo-Gallego, R., Cofán, M., Plana, N., Puzo, J., Burillo, E., Martín-Fuentes, P., Ros, E., Masana, L., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.03.011 · Cited by 74
Flagged first, then by citations
Research works printed but not linked: 1
- Mahley, 1989, The metabolic basis of inherited diseases, 1195
Cited by
Sorted by citations
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., & Seidah, N. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064145 · Cited by 227
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170
Self-citationGenetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 158
Self-citationLipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias
Johansen, C. T., Dubé, J. B., Loyzer, M. N., MacDonald, A., Carter, D. E., McIntyre, A. D., Cao, H., Wang, J., Robinson, J. F., & Hegele, R. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.d045963 · Cited by 125
Paththinige, C., Sirisena, N., & Dissanayake, V. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0488-4 · Cited by 118
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationGenetic Architecture of Familial Hypercholesterolaemia
Sharifi, M., Futema, M., Nair, D. R., & Humphries, S. E. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0848-8 · Cited by 116
Targeted next-generation sequencing in monogenic dyslipidemias
Hegele, R. A., Ban, M. R., Cao, H., McIntyre, A. D., Robinson, J. F., & Wang, J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000163 · Cited by 106
APOE p.Leu167del mutation in familial hypercholesterolemia
Awan, Z. A., Choi, H. Y., Stitziel, N. O., Ruel, I. L., Bamimore, M. A., Husa, R., Gagnon, M.-H., Wang, R.-H. L., Peloso, G. M., Hegele, R. A., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.007 · Cited by 115
Self-citationCenarro, A., Etxebarria, A., de Castro-Orós, I., Stef, M., Bea, A. M., Palacios, L., Mateo-Gallego, R., Benito-Vicente, A., Ostolaza, H., Tejedor, T., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3874 · Cited by 100
Genetics of Familial Hypercholesterolemia
Brautbar, A., Leary, E. J. W., Rasmussen, K., Wilson, D. P., Steiner, R. D., & Virani, S. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0491-z · Cited by 103
Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia
Alves, A. C., Etxebarria, A., Soutar, A. K., Martı́n, C., & Bourbon, M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt573 · Cited by 95
Pirillo, A., Garlaschelli, K., Arca, M., Averna, M. R., Bertolini, S., Calandra, S., Tarugi, P., Catapano, A. L., Arca, M., Averna, M. R., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.002 · Cited by 88
Mayer, G., & Poirier, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 89
Familial hypercholesterolemia: A complex genetic disease with variable phenotypes
Taranto, M. D. D., Giacobbe, C., & Fortunato, G. (2019) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2019.103831 · Cited by 87
Ason, B. L., van der Hoorn, J. W. A., Chan, J. C. Y., Lee, E. W., Pieterman, E. J., Nguyen, K., Di, M., Shetterly, S., Tang, J. T., Yeh, W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 83
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 78
Ramaswami, U., Humphries, S. E., Priestley-Barnham, L., Green, P., Wald, D. S., Capps, N. E., Anderson, M., Dale, P., & Morris, A. A. M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.005 · Cited by 75
Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia
Futema, M., Bourbon, M., Williams, M., & Humphries, S. E. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.006 · Cited by 76
Marais, A. D., Solomon, G. A. E., & Blom, D. J. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.870526 · Cited by 70
Saavedra, Y. G. L., Day, R. W., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394023 · Cited by 73
Exome sequencing greatly expedites the progressive research of Mendelian diseases
Zhang, X. (2014) · Frontiers of Medicine · doi:10.1007/s11684-014-0303-9 · Cited by 58
Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
Naeli, P., Mirzadeh Azad, F., Malakootian, M., Seidah, N. G., & Mowla, S. J. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00189 · Cited by 58
Exome Sequencing in Suspected Monogenic Dyslipidemias
Stitziel, N. O., Peloso, G. M., Abifadel, M., Cefalu, A. B., Fouchier, S. W., Motazacker, M. M., Tada, H., Larach, D. B., Awan, Z. A., Haller, J. F., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000776 · Cited by 54
Self-citationManagement of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 63
Lahtinen, A. M., Havulinna, A. S., Jula, A., Salomaa, V. V., & KONTULA, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.11.015 · Cited by 52
Genetic testing for familial hypercholesterolemia—past, present, and future
Futema, M., Taylor-Beadling, A., Williams, M., & Humphries, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100139 · Cited by 50
Wintjens, R., Bozon, D., Belabbas, K., MBou, F., Girardet, J.-P., Tounian, P., Jolly, M., Boccara, F., Cohen, A., Karsenty, A., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p055699 · Cited by 47
Iacocca, M. A., Wang, J., Sarkar, S. K., Dron, J. S., Lagace, T. A., McIntyre, A. D., Lau, P., Robinson, J. F., Yang, P., Knoll, J. H. M., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.479 · Cited by 46
Awan, Z. A., Baass, A. W., & Genest, J. J. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.225946 · Cited by 44
Mining the genome for lipid genes
Kuivenhoven, J. A., & Hegele, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.028 · Cited by 45
Next generation sequencing applications for cardiovascular disease
Kalayinia, S., Goodarzynejad, H., Maleki, M., & Mahdieh, N. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1392595 · Cited by 45
Taking One Step Back in Familial Hypercholesterolemia
Loaiza, N., Hartgers, M. L., Reeskamp, L. F., Balder, J.-W., Rimbert, A., Bazioti, V., Wolters, J. C., Winkelmeijer, M., Jansen, H., Dallinga‐Thie, G. M., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313470 · Cited by 44
My Approach to the Patient With Familial Hypercholesterolemia
Safarova, M. S., & Kullo, I. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.013 · Cited by 42
Foody, J. M., & Vishwanath, R. L. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.009 · Cited by 40
Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis
Taranto, M. D. D., & Fortunato, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043224 · Cited by 45
Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia
Sarraju, A., & Knowles, J. W. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00005 · Cited by 42
Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype
Awan, Z. A., DELVIN, E. E., Levy, E. H., Genest, J. J., Davignon, J., Seidah, N. G., & Baass, A. W. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.03.004 · Cited by 41
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 38
Molecular basis of familial hypercholesterolemia
Bruikman, C. S., Hovingh, G. K., & Kastelein, J. J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000385 · Cited by 37
Futema, M., Ramaswami, U., Tichý, L., Bogsrud, M. P., Holven, K. B., van Lennep, J. E. R., Wiegman, A., Descamps, O. S., Leener, A. D., Fastré, E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.008 · Cited by 39
Elbitar, S., Susan‐Resiga, D., Ghaleb, Y., Khoury, P. E., Peloso, G. M., Stitziel, N. O., Rabès, J., Carreau, V., Hamelin, J., Ouadda, A. B. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20281-9 · Cited by 35
Self-citationProgress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Taranto, M. D. D., Giacobbe, C., Palma, D., Iannuzzo, G., Gentile, M., Calcaterra, I. L., Guardamagna, O., Auricchio, R., Minno, M. N. D. D., & Fortunato, G. (2021) · Clinical Genetics · doi:10.1111/cge.14036 · Cited by 36
Mariano, C., Alves, A. C., Medeiros, A. M., Chora, J. R., Antunes, M. C. D. S., Futema, M., Humphries, S. E., & Bourbon, M. (2019) · Clinical Genetics · doi:10.1111/cge.13697 · Cited by 30
Sun, D., Zhou, B., Li, S., Sun, N., Hua, Q., Wu, S., Cao, Y., Guo, Y., Wu, N., Zhu, C., et al. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0900-8 · Cited by 30
Pek, S. L. T., Dissanayake, S., Fong, J. C. W., Lin, M. X., Chan, E. Z. L., Tang, J. I.-S., Lee, C. W., Ong, H. Y., Sum, C. F., Lim, S. C., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.028 · Cited by 27
Heidemann, B. E., Koopal, C., Baass, A., Defesche, J. C., Zuurbier, L., Mulder, M. T., Roeters van Lennep, J. E., Riksen, N. P., Boot, C., Marais, A. D., et al. (2022) · Clinical Genetics · doi:10.1111/cge.14185 · Cited by 27
Hooper, A. J., Burnett, J. R., Bell, D. A., & Watts, G. F. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0731-0 · Cited by 27
Genes Potentially Associated with Familial Hypercholesterolemia
Михайлова, С. В., Иванощук, Д. Е., Тимощенко, О. В., & Шахтшнейдер, Е. В. (2019) · Biomolecules · doi:10.3390/biom9120807 · Cited by 25
Medeiros, A. M., Alves, A. C., Miranda, B., Chora, J. R., Bourbon, M., Bourbon, M., Rato, Q., Alves, A. C., Medeiros, A. M., Gomes, A. C., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100490 · Cited by 25
Familial combined hyperlipidemia is a polygenic trait
Gill, P. K., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000796 · Cited by 24
Next-generation sequencing applied to rare diseases genomics
Danielsson, K., Mun, L. J., Lordemann, A., Mao, J., & Lin, C.-H. J. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.904749 · Cited by 24
Olmastroni, E., Gazzotti, M., Arca, M., Averna, M., Pirillo, A., Catapano, A. L., Casula, M., Bertolini, S., Calandra, S., Tarugi, P., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023668 · Cited by 23
Ghaleb, Y., Elbitar, S., Khoury, P. E., Bruckert, É., Carreau, V., Carrié, A., Moulin, P., Filippo, M. D., Charrière, S., Iliozer, H., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-017-0078-y · Cited by 23
Self-citationSéguro, F., Rabès, J., Taraszkiewicz, D., Ruidavets, J., Bongard, V., & Ferrières, J. (2018) · Clinical Cardiology · doi:10.1002/clc.22881 · Cited by 23
Self-citationAPOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia
Abou Khalil, Y., Marmontel, O., Ferrières, J., Paillard, F., Yelnik, C., Carreau, V., Charrière, S., Bruckert, E., Gallo, A., Giral, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105792 · Cited by 21
Self-citationExome Sequencing: New Insights into Lipoprotein Disorders
Farhan, S. M. K., & Hegele, R. A. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0507-2 · Cited by 20
Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia
Rieck, L., Bardey, F., Grenkowitz, T., Bertram, L., Helmuth, J., Mischung, C., Spranger, J., Steinhagen‐Thiessen, E., Bobbert, T., Kassner, U., et al. (2020) · Clinical Genetics · doi:10.1111/cge.13826 · Cited by 21
de la Vega, M. P., Näslund, C., Brundin, R., Lannfelt, L., Löwenmark, M., Kilander, L., Ingelsson, M., & Giedraitis, V. (2022) · BMC Genomics · doi:10.1186/s12864-022-08343-9 · Cited by 21
Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 22
Al-Allaf, F. A., H.Nazar, F. A., Alnefaie, M., Almaymuni, A., Rashidi, O. M., AlHabib, K. F., Alnouri, F., Alama, M.-N., Athar, M., & Awan, Z. A. (2017) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401711010066 · Cited by 19
Hsiung, Y.-C., Lin, P., Chen, C.-S., Tung, Y., Yang, W., Chen, P., & Su, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.022 · Cited by 17
Consenso de expertos sobre la detección y el manejo clínico de la hipercolesterolemia familiar
Masana, L., Civeira, F., Pedro‐Botet, J., de Castro-Orós, I., Pocovı́, M., Plana, N., Mateo‐Gállego, R., Jarauta, E., & Pedragosa, À. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.07.005 · Cited by 16
Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9
Alkindi, M., Siminovitch, K. A., Gupta, M., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.04.013 · Cited by 15
Rashidi, O. M., H.Nazar, F. A., Alama, M. N., & Awan, Z. A. (2017) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401711010084 · Cited by 17
Martín-Campos, J. M., Plana, N., Figueras, R., Ibarretxe, D., Caixàs, A., Esteve, E., Pérez, A., Bueno, M., Mauri, M., Roig, R., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.09.002 · Cited by 15
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14
APOE and familial hypercholesterolemia
Civeira, F., Martín, C., & Cenarro, A. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000937 · Cited by 15
Cao, Y., Sun, D., Liu, H., Jin, J., Li, S., Guo, Y., Wu, N., Zhu, C., Liu, G., Dong, Q., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.04.001 · Cited by 13
Genetic testing for familial hypercholesterolemia
Zhang, Y., de Ferranti, S. D., & Moran, A. E. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000925 · Cited by 12
Kalwick, M., & Roth, M. M. (2025) · Nutrients · doi:10.3390/nu17040659 · Cited by 13
Humphries, S. E., Ramaswami, U., & Hopper, N. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01177-0 · Cited by 11
A novel indel variant in LDLR responsible for familial hypercholesterolemia in a Chinese family
Shu, H., Chi, J., Li, J., Zhang, W., Lv, W., Wang, J., Deng, Y., Hou, X., & Wang, Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189316 · Cited by 10
Genetic Determinants of the Familial Hypercholesterolaemia Phenotype
Humphries, S. E., & Futema, M. (2025) · Annals of Human Genetics · doi:10.1111/ahg.12594 · Cited by 11
Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia
Marmontel, O., Abou-Khalil, Y., Bluteau, O., Cariou, B., Carreau, V., Charrière, S., Divry, E., Gallo, A., Moulin, P., Paillard, F., et al. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319146 · Cited by 9
Self-citationOkorodudu, D. E., Crowley, M. J., Sebastian, S., Rowell, J. V., & Guyton, J. R. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.09.003 · Cited by 9
Current novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement
Fouchier, S. W., Hutten, B. A., & Defesche, J. C. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102653 · Cited by 9
Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene
Leren, T. P., Strøm, T. B., & Berge, K. E. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.10.007 · Cited by 8
Self-citationBird, M., Rimbert, A., Pittman, A. M., Humphries, S., & Futema, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae371 · Cited by 9
Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL‐C and LPA genetic scores
Schwaninger, G., Forer, L., Ebenbichler, C. F., Dieplinger, H., Kronenberg, F., Zschocke, J., & Witsch‐Baumgartner, M. (2023) · Clinical Genetics · doi:10.1111/cge.14387 · Cited by 10
Impact of rare variants in autosomal dominant hypercholesterolemia causing genes
Calandra, S., Tarugi, P., & Bertolini, S. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000414 · Cited by 7
Muñoz, G., García‐Seisdedos, D., Ciubotariu, C., Piris‐Villaespesa, M., Gandía, M., Martín‐Moro, F., Gutiérrez-Solana, L. G., Morado, M., López‐Jiménez, J., Sánchez-Herranz, A., et al. (2019) · JIMD Reports · doi:10.1002/jmd2.12078 · Cited by 7
Ashfield-Watt, P. A. L., Haralambos, K., Edwards, R. M., Townsend, D., Gingell, R., Li, K. W., Humphries, S. E., & McDowell, I. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218793165 · Cited by 7
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Page, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
Lee, W., Chuang, H., Hsiao, T., Lee, W.-L., Wu, J.-P., Sheu, W. H., & Liang, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44065-y · Cited by 7
The fine line between familial and polygenic hypercholesterolemia
de Castro-Orós, I., Pocovı́, M., & Civeira, F. (2013) · Clinical Lipidology · doi:10.2217/clp.13.20 · Cited by 6
Campagna, J. J., Chandra, S., Teter, B., Cohn, W., Pham, J. D., Kim, Y.-S., Jagodzinska, B. M., Vadivel, K., Alam, P., Bilousova, T. V., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96131-2 · Cited by 7
Benito‐Vicente, A., Uribe, K. B., Larrea, A., Palacios, L., Cenarro, A., Calle, X., Galicia-García, U., Jebari‐Benslaiman, S., Sánchez-Hernández, R. M., Stef, M. A., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.315499 · Cited by 6
Update on genetics of familial hypercholesterolemia
Freiberger, T. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001027 · Cited by 5
Martín-Campos, J. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111728 · Cited by 4
Schatoff, D., Jung, I. Y., & Goldberg, I. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.009 · Cited by 5
Familial hypercholesterolaemia: what’s new?
Ramaswami, U., & Humphries, S. E. (2019) · Paediatrics and Child Health · doi:10.1016/j.paed.2019.01.006 · Cited by 4
Genomics of familial hypercholesterolaemia
Alves, A. C., Chora, J. R., & Bourbon, M. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000584 · Cited by 4
Inborn Errors of Lipoprotein Metabolism Presenting in Childhood
Ramaswami, U., & Humphries, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_36 · Cited by 4
Novel start codon variant in the 5’UTR of LDLR associated with familial hypercholesterolaemia
Bird, M., Tung, C. J.-P., Pittman, A. M., Behr, E. R., Nohturfft, A., & Futema, M. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01893-y · Cited by 4
Familiäre Hypercholesterinämie – Diagnose und Therapie
Schöb, M., Müller, P., Gerth, Y., Korte, W. C., Rickli, H., Brändle, M., Bärlocher, A., & Bilz, S. (2018) · Praxis · doi:10.1024/1661-8157/a003134 · Cited by 3
Totoń‐Żurańska, J., Wołkow, P. P., Kapusta, M., Wójcik, M., Starzyk, J., Kawalec, E., Idzior−Waluś, B., & Waluś‐Miarka, M. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16417 · Cited by 4
Metadata
- Authors
- Marduel, M., Ouguerram, K., Serre, V., Bonnefont-Rousselot, D., Marques-Pinheiro, A., Erik Berge, K., Devillers, M., Luc, G., Lecerf, J.-M., Tosolini, L., Erlich, D., Peloso, G. M., Stitziel, N., Nitchké, P., Jaïs, J.-P., The French Research Network on ADH, Abifadel, M., Kathiresan, S., Leren, T. P., Rabès, J.-P., Boileau, C., & Varret, M.
- Affiliations
- Inserm (FR)
- Medical Genetics Laboratory; Oslo University Hospital Rikshospitalet; Oslo; Norway
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Université Paris Denis Diderot; Paris; France
- Broad Institute (US)
- Hôpital Necker-Enfants Malades (FR)
- Oslo University Hospital (NO)
- Corresponding author
- Varret, Mathilde
- ORCID
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2012-10-11
- Volume
- 34
- Issue
- 1
- Pages
- 83-87
- ISSN
- 1059-7794 (ISSN-L)
- PMC
- PMC3638718
- OpenAlex
- W2072770085
- Semantic Scholar
- e4d31a1313c36bcd4d0998701fcdf0156fa0f973
- Cited by
- 133
- References
- 32
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 12 · 2017: 12 · 2016: 9 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 1
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Human Mutation (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-05-PCOD-0017, ANR-08-GENO-0002, ANR-06-MRAR-0038)
- National Heart, Lung, and Blood Institute (R01HL107816)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- autosomal dominant hypercholesterolemia, apolipoprotein E, familial hypercholesterolemia, LDL receptor, apolipoprotein B, PCSK9, type III hyperlipoproteinemia, LDL catabolism, family studies, exome sequencing, genome-wide mapping
- MeSH terms
- Adolescent, Adult, Apolipoproteins E, Child, Cholesterol, Chromosomes, Human, Pair 19, Family Health, Female, Haplotypes, Humans, Hyperlipoproteinemia Type II, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Models, Molecular, Mutation, Pedigree, Triglycerides, Gene Deletion, Protein Structure, Secondary, Protein Structure, Tertiary, Genetic Predisposition to Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-31, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-31 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
